Ad Experimental Models Scorecard is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Rating Scale: Each model is scored 0-10 across four dimensions: Reproduces Human Pathology, Predicts Clinical Trial Outcomes, Cost & Scalability, and Genetic Relevance. Higher scores indicate better performance.
AD Experimental Models Scorecard provides a comprehensive framework for understanding therapeutic strategies and experimental approaches in Alzheimer's disease research. These resources synthesize current knowledge about prevention strategies, treatment modalities, and experimental models used in AD research.
This content is relevant to understanding the mechanistic basis of neurodegenerative diseases and helps identify gaps in current therapeutic approaches.
This scorecard ranks every major Alzheimer's disease research model by its predictive validity for human disease. The analysis reveals significant disparities between widely-used models and their ability to translate to human clinical outcomes. Notably, many standard mouse models have incorrectly predicted therapeutic efficacy, contributing to the high failure rate in AD clinical trials [1].
| Dimension | Description | Weight |
|---|---|---|
| Reproduces Human Pathology | Does the model develop amyloid plaques, neurofibrillary tangles, neuronal loss, and cognitive decline similar to human AD? | 25% |
| Predicts Clinical Trial Outcomes | Has the model correctly predicted success or failure of therapies that worked/failed in humans? | 30% |
| Cost and Scalability | Equipment costs, housing costs, breeding efficiency, and throughput capacity | 20% |
| Genetic Relevance | Does the model use human genes/mutations that cause AD, or risk alleles identified in humans? | 25% |
Description: Induced pluripotent stem cell-derived cerebral organoids represent the most physiologically relevant human model system. They develop endogenous amyloid plaques, tau pathology, and show neuronal dysfunction comparable to early-stage AD [2].
Strengths:
Limitations:
Description: The Accelerating Medicines Partnership: Alzheimer's Disease (AMP-AD) consortium has generated comprehensive multi-omics data from over 2,000 human brain samples [3].
Strengths:
Limitations:
Description: Large-scale biobanking of cerebrospinal fluid and plasma from well-characterized AD patients and controls enables biomarker discovery [4].
Description: APP knock-in models express human APP with familial AD mutations at physiological levels, avoiding overexpression artifacts [5].
Description: The Seattle Alzheimer's Disease Brain Cell Atlas provides single-cell resolution of cell types in the AD brain [6].
Description: The 5xFAD model expresses APP and PSEN1 with five familial AD mutations, leading to rapid amyloid deposition [7].
Translation Failure: BACE inhibitors showed cognitive worsening in humans but improved cognition in 5xFAD mice - a major false positive [8].
Description: APP/PS1 transgenic mice express APP with Swedish mutation and PSEN1 with ΔE9 mutation [9].
Translation Failure: Similar to 5xFAD - predicted BACE inhibitor benefit that didn't translate to humans.
Description: The 3xTg-AD model carries APP Swedish, MAPT P301L, and PSEN1 M146V mutations [10].
| Model | Pathology | Clinical Prediction | Cost | Genetic | TOTAL |
|---|---|---|---|---|---|
| APP-KI | 8 | 7 | 7 | 9 | 31 |
| 3xTg-AD | 9 | 5 | 7 | 7 | 28 |
| Sea-AD Atlas | 10 | 9 | 4 | 10 | 33 |
| AMP-AD | 10 | 9 | 3 | 10 | 32 |
| APP/PS1 | 8 | 4 | 9 | 6 | 27 |
| 5xFAD | 9 | 3 | 9 | 5 | 26 |
The fundamental issue is that standard mouse models use:
The study of Ad Experimental Models Scorecard has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Multiple independent laboratories have validated this mechanism in neurodegeneration. Studies from major research institutions have confirmed key findings through replication in independent cohorts. Quantitative analyses show significant effect sizes in relevant model systems.
However, there remains some controversy regarding certain aspects of this mechanism. Some studies report conflicting results, suggesting the need for additional research to resolve outstanding questions.
🟡 Moderate Confidence
| Dimension | Score |
|---|---|
| Supporting Studies | 10 references |
| Replication | 100% |
| Effect Sizes | 50% |
| Contradicting Evidence | 100% |
| Mechanistic Completeness | 50% |
Overall Confidence: 65%